Literature DB >> 28811927

Premature deaths among individuals with severe mental illness after discharge from long-term hospitalisation in Japan: a naturalistic observation during a 24-year period.

Shinsuke Kondo1, Yousuke Kumakura2, Akiko Kanehara3, Daisuke Nagato4, Taro Ueda4, Tsuneo Matsuoka5, Yukiko Tao4, Kiyoto Kasai6.   

Abstract

BACKGROUND: Premature death in individuals with severe mental illness (SMI) in countries without nationally collected data, including Japan, is structurally underreported. AIMS: To elucidate excess mortality among individuals with SMI in Japan.
METHOD: We retrospectively investigated all deaths among users of a non-clinical community-based mental health service provider in suburban Tokyo from 1992 to 2015.
RESULTS: During the study period, 45 individuals died among 254 qualified registrants. Deaths were by natural causes in 33 cases (73.3%). The mean years of life lost was 22.2 years and the overall standard mortality ratio (SMR) was 3.28 (95% CI 2.40-4.39). The cause-specific SMR was 5.09 (95% CI 2.33-9.66) for cardiovascular disease and 7.38 (95% CI 2.40-17.22) for suicide.
CONCLUSIONS: Although Japan leads the world in longevity, individuals with SMI suffer premature death and excess mortality due to physical conditions as well as suicide. Revealing this underreported disparity of life is the first step to improving physical care for individuals with SMI. DECLARATION OF INTEREST: S.K. received personal fees from Pfizer and Dainippon-Sumitomo, outside the submitted work, and was a medical adviser to Sudachi-kai. Y.K. received grants from Japan Foundation for Neuroscience and Mental Health (JFNMH), during the conduct of the study, and personal fees from Dainippon-Sumitomo, outside the submitted work. K.K. received grants from Japan Society for the Promotion of Science (JSPS) and Japan Agency for Medical Research and Development (AMED), during the conduct of the study; personal fees from Daiichi-Sankyo, Otsuka, Meiji-Seika Pharma, Yoshitomi, Mochida and Fuji-Film RI Pharma; grants and personal fees from MSD, Astellas, Dainippon-Sumitomo and Eisai; and grants from Lily, Takeda and Tanabe-Mitsubishi, outside the submitted work. COPYRIGHT AND USAGE: © The Royal College of Psychiatrists 2017. This is an open access article distributed under the terms of the Creative Commons Non-Commercial, No Derivatives (CC BY-NC-ND) license.

Entities:  

Year:  2017        PMID: 28811927      PMCID: PMC5553043          DOI: 10.1192/bjpo.bp.117.004937

Source DB:  PubMed          Journal:  BJPsych Open        ISSN: 2056-4724


Premature deaths among individuals with severe mental illness (SMI) are extensively documented.[1] However, most evidence originates from countries with an available large database or national registry. Little is known regarding this issue in countries without nationally collected data, including Japan. We aimed to elucidate excess mortality among individuals with SMI in Japan.

Method

We retrospectively investigated all deaths among users of a non-clinical, community-based non-profit organisation for individuals with SMI in suburban Tokyo from 1992 to 2015. The organisation, Sudachi-kai (Mitaka, Tokyo), is reportedly one of the best practice community mental health service providers in Japan.[2] Sudachi-kai has promoted the discharge of hospitalised individuals with SMI to community living, offering case management, supported accommodations, and vocational training, with no time limit. The inclusion criteria were as follows: the individual entered the service after discharge from long-term in-patient treatment at a psychiatric hospital, was diagnosed with a chronic psychiatric disorder and was receiving out-patient psychiatric care. The study period for each registrant extended from the entry into the service to the termination of service use, including death. The registrants who left the service and became untraceable were included until the time at which they left the service. All available records of the deceased registrants were carefully examined with the local social workers who personally knew each registrant. Extracted data included age, cause and situation of death, living environment (including accommodations), financial status, marital status, cigarette smoking and medical history. Years of life lost (YLL) were calculated by summing the gender-specific life expectancy at the age of death using the national life table for the year of the death.[3] Mean YLL (YLL per person) was calculated by dividing the YLL by total number of deaths. Mortality rates were estimated using the person-year method: overall, gender-specific and cause-specific standard mortality ratios (SMRs) were calculated by dividing the observed deaths by the expected deaths. Expected deaths were estimated from the sum total of an annual age-/gender-specific mortality rate in the general population corresponding to each person-year using the national vital statistics for the study period.[3,4] Confidence intervals (CIs) of the SMRs were computed based on the Poisson distribution. Statistical analyses were performed using R software (version 2.14.1; www.r-project.org). The study protocol was disclosed to the public on the websites of the Department of Neuropsychiatry at the University of Tokyo Hospital and Sudachi-kai. This study was approved by the research ethics committee of the Faculty of Medicine at the University of Tokyo.

Results

During the study period, there were 254 qualified registrants (1983 person-years). Average age at entry was 50.0 years (s.d.=11.8). The living statuses of 180 registrants (1526 person-years) were confirmed at the end of 2015, whereas those who became untraceable were included until the time at which they left the service (457 person-years). Among these, 45 individuals (31 men and 14 women) died during the study period. All of the deceased had an SMI under treatment (schizophrenia 39, other psychotic disorder 1, bipolar disorder 3, depression 1 and other 1). Among the deceased, the cumulative length of the psychiatric hospital stay ranged from 1.1 to 47.8 years, with an average of 15.6 years (s.d.=12.0). The mean age at death was 63 years (men, 63.2 years; women, 62.6 years). The mean YLL was 22.2 years (men, 20.5 years; women, 26.0 years). The leading causes of death included cancer of any origin (10 (22.2%)), cardiovascular disease (9 (20.0%)) and suicide (5 (11.1%)). Natural causes were responsible for 33 (73.3%) of the deaths. Sudden death occurred in one-third of the deaths (15 (33.3%)). The death was unattended for 12 individuals (26.7%). Among the deceased, 42 individuals (93%) had been living either independently or semi-independently; 39 (87%) had received social welfare or disability benefits (or both). Majority of the deceased (27 (60.0%)) had regularly visited non-psychiatric physicians for chronic conditions such as diabetes and hypertension. Twenty-two individuals (49%) were smokers at the time of death. The overall SMR of the study group was 3.28 (95%CI 2.40–4.39). The gender-specific SMR was 2.85 (95%CI 1.93–4.04) for men and 4.98 (95%CI 2.72–8.35) for women. The cause-specific SMR was 1.94 (95%CI 0.93–3.57) for cancer, 5.09 (95%CI 2.33–9.66) for cardiovascular disease and 7.38 (95%CI 2.40–17.22) for suicide. Detailed results are summarised in Table 1.
Table 1

Registrant characteristics and computed standard mortality ratios (SMRs)

Total n (%)SMR (95% CI)
Survivors209
Deaths45 (100)3.28 (2.40–4.39)
 Male31 (68.9)2.85 (1.93–4.04)
 Female14 (31.1)4.98 (2.72–8.35)
Cause of death
 Natural death33 (73.3)
 Cancer10 (22.2)1.94 (0.93–3.57)
 Cardiovascular disease9 (20.0)5.09 (2.33–9.66)
 Other diseases14 (31.1)
 Suicide5 (11.1)7.38 (2.40–17.22)
 Accident2 (4.4)
 Unknown5 (11.1)
Sudden death15 (33.3)
Accommodation after discharge
 Independent living17 (37.8)
 Group home25 (55.6)
 Nursing home2 (4.4)
 Living with family1 (2.2)
Financial status
 Social welfare29 (64.4)
 Disability benefits24 (53.3)
 Both14 (31.1)
 Unknown2 (4.4)
Marital status
 Never married22 (48.9)
 Were married (including divorced)13 (28.9)
 Unknown10 (22.2)
Cigarette smoking
 Smoker22 (48.9)
 Non-smoker18 (40.0)
 Unknown5 (11.1)
Medical treatment
 Regular psychiatric visits45 (100.0)
 Regular medical visits27 (60.0)
Unattended death12 (26.7)

CI, confidence interval; SMR, standard mortality ratio.

CI, confidence interval; SMR, standard mortality ratio.

Discussion

We found that the individuals with SMI died approximately 20 years early relative to the general population, mostly from natural causes. The overall and gender-specific SMRs were significantly elevated, as well as those for cardiovascular disease and suicide. These results are consistent with the previous literature,[5] and for the first time, they demonstrate the premature death of individuals with SMI in the world’s leading country for longevity. Few reports exist regarding excess mortality in individuals with SMI in Japan, all of which are based on hospital records prior to the 1980s.[6,7] The lack of publications after this era may be due to methodological limitations related to a difficulty in linking psychiatric patients with vital statistics in Japan. Moreover, the OECD Reviews of Health Care Quality[8] pointed out that Japan is unable to report on any of the indicators collected under the OECD Health Care Quality Indicator collection for mental health. This lack of database infrastructure may itself reflect a structural neglect of this population. This study has several limitations. First, this is a small, single-centre study, which may limit generalisation. Additionally, the average age of 50 years at entry suggests that the study group may reflect a survival group from earlier potential deaths, particularly from suicide. However, this study can be generalised to some extent, because such individuals illustrate a typical picture of a socially marginalised life course after discharge from long-term hospitalisation in a real-world setting. Although this study included incomplete data from those who became untraceable, it does provide some evidence on the mortality gap in the absence of alternative available data. The strengths of this study include its ability to offer personal information that would not appear in large-scale population-based data. The fact that the majority of the deceased regularly visited physicians in addition to usual psychiatric visits may indicate that access to physical healthcare was apparently provided, but not in an integrative and effective way.[9] In countries such as Japan, where physical and mental healthcare systems are dichotomised, multilevel actions under strong leadership are necessary to facilitate communication and improve physical care for individuals with SMI.[10] Revealing this underreported disparity of life is the first step.
  7 in total

1.  An epidemiologic study of deaths of psychiatric inpatients.

Authors:  H Shinozaki
Journal:  Compr Psychiatry       Date:  1976 May-Jun       Impact factor: 3.735

2.  The ongoing development of community mental health services in Japan: utilizing strengths and opportunities.

Authors:  Chee Ng; Yutaro Setoya; Asuka Koyama; Tadashi Takeshima
Journal:  Australas Psychiatry       Date:  2010-02       Impact factor: 1.369

3.  Physical health disparities and mental illness: the scandal of premature mortality.

Authors:  Graham Thornicroft
Journal:  Br J Psychiatry       Date:  2011-12       Impact factor: 9.319

Review 4.  Excess early mortality in schizophrenia.

Authors:  Thomas Munk Laursen; Merete Nordentoft; Preben Bo Mortensen
Journal:  Annu Rev Clin Psychol       Date:  2013-12-02       Impact factor: 18.561

Review 5.  Mortality in mental disorders and global disease burden implications: a systematic review and meta-analysis.

Authors:  Elizabeth Reisinger Walker; Robin E McGee; Benjamin G Druss
Journal:  JAMA Psychiatry       Date:  2015-04       Impact factor: 21.596

6.  Mortality in psychiatric patients, with a specific focus on cancer mortality associated with schizophrenia.

Authors:  M Saku; S Tokudome; M Ikeda; S Kono; K Makimoto; H Uchimura; A Mukai; T Yoshimura
Journal:  Int J Epidemiol       Date:  1995-04       Impact factor: 7.196

7.  Excess mortality in persons with severe mental disorders: a multilevel intervention framework and priorities for clinical practice, policy and research agendas.

Authors:  Nancy H Liu; Gail L Daumit; Tarun Dua; Ralph Aquila; Fiona Charlson; Pim Cuijpers; Benjamin Druss; Kenn Dudek; Melvyn Freeman; Chiyo Fujii; Wolfgang Gaebel; Ulrich Hegerl; Itzhak Levav; Thomas Munk Laursen; Hong Ma; Mario Maj; Maria Elena Medina-Mora; Merete Nordentoft; Dorairaj Prabhakaran; Karen Pratt; Martin Prince; Thara Rangaswamy; David Shiers; Ezra Susser; Graham Thornicroft; Kristian Wahlbeck; Abe Fekadu Wassie; Harvey Whiteford; Shekhar Saxena
Journal:  World Psychiatry       Date:  2017-02       Impact factor: 49.548

  7 in total
  3 in total

1.  Metabolic changes of Japanese schizophrenic patients transferred from hospitalization to outpatients.

Authors:  Yoriyasu Uju; Tetsuto Kanzaki; Yuki Yamasaki; Tadayuki Kondo; Hideki Nanasawa; Yu Takeuchi; Yuta Yanagisawa; Shun Kusanishi; Chieko Nakano; Tetsuro Enomoto; Akahito Sako; Hidekatsu Yanai; Seisuke Mimori; Kazuei Igarashi; Tsuyoshi Takizawa; Tatsuro Hayakawa
Journal:  Glob Health Med       Date:  2020-06-30

2.  A cross-sectional study on metabolic similarities and differences between inpatients with schizophrenia and those with mood disorders.

Authors:  Yoriyasu Uju; Tetsuto Kanzaki; Yuki Yamasaki; Tadayuki Kondo; Hideki Nanasawa; Yu Takeuchi; Yuta Yanagisawa; Shun Kusanishi; Chieko Nakano; Tetsuro Enomoto; Akahito Sako; Hidekazu Yanai; Shunichi Mishima; Seisuke Mimori; Kazuei Igarashi; Tsuyoshi Takizawa; Tatsuro Hayakawa
Journal:  Ann Gen Psychiatry       Date:  2020-09-22       Impact factor: 3.455

3.  Prescription patterns in patients with schizophrenia in Japan: First-quality indicator data from the survey of "Effectiveness of Guidelines for Dissemination and Education in psychiatric treatment (EGUIDE)" project.

Authors:  Kayo Ichihashi; Hikaru Hori; Naomi Hasegawa; Yuka Yasuda; Tomoya Yamamoto; Takashi Tsuboi; Kunihiro Iwamoto; Taishiro Kishimoto; Tadasu Horai; Hiroki Yamada; Nobuhiro Sugiyama; Toshinori Nakamura; Naohisa Tsujino; Kiyotaka Nemoto; Satoru Oishi; Masahide Usami; Eiichi Katsumoto; Hidenaga Yamamori; Hiroaki Tomita; Taro Suwa; Ryuji Furihata; Takahiko Inagaki; Junichi Fujita; Toshiaki Onitsuka; Kenichiro Miura; Junya Matsumoto; Kazutaka Ohi; Yuki Matsui; Yoshikazu Takaesu; Naoki Hashimoto; Junichi Iga; Kazuyoshi Ogasawara; Hisashi Yamada; Koichiro Watanabe; Ken Inada; Ryota Hashimoto
Journal:  Neuropsychopharmacol Rep       Date:  2020-06-30
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.